Azra AI Introduces Agentic AI Clinical Research Platform
Azra AI announced in a press release the launch of its Agentic AI Clinical Research Platform, designed to connect health systems and pharmaceutical companies through a unified patient intelligence layer. The platform builds on Azra AI’s care orchestration engine to harmonize fragmented electronic health record data for use across the clinical trial lifecycle.
The system processes pathology and radiology reports as soon as they enter the EHR, applying AI models to detect and characterize diseases including oncology, cardiology, and neurology. This real time data ingestion identifies trial eligible patients up to seven days earlier than traditional systems.
The platform includes a conversational user interface that allows researchers to interact with data using natural language, reducing site feasibility assessments from weeks to seconds. Autonomous AI agents continuously scan data to automate pre screening and enrollment, while predictive tools track disease progression to identify patients for upcoming trials.
Azra AI also introduced the Azra Clinical Research Network, enabling hospitals to connect directly with pharmaceutical studies suited to their patient populations. The platform provides automated reporting and full traceability to source data, offering transparency and oversight across the entire trial portfolio.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly, Sales & Marketing AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
TRI Launches TRIAL.OS for Clinical Trial Management
AKASA Launches Autonomous AI Platform for Inpatient Coding
TRI adds AI risk assessment to OPRA clinical trial platform
AI in Clinical Trials Market Forecast to Reach USD 7.32 Billion by 2034
The Saffron Solution Brings AI Workflow Tools to AAO 2026
Daily AI Brief: the AI news that matters, in your inbox.